NCT01292304View on ClinicalTrials.gov

Tolvaptan for Ascites in Cirrhotic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions
AscitesCirrhosis
Interventions
DRUG

Tolvaptan

Oral administration once daily Dosage will range from 15 mg to 30 mg

Trial Locations (1)

32610-0277

University of Florida Hepatology, Gainesville

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

University of Florida

OTHER